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Introduction
Vaccinia virus is the prototypical member of the large DNA vi-
rus family Poxviridae. Like all poxviruses, vaccinia exhibits signif-
icant autonomy from the host cell and carries out its entire life-
cycle in the cytoplasm. The fact that vaccinia virus is capable of 
both DNA replication and transcription in this location is unique 
among DNA viruses, and is achieved by a large repertoire of virus-
encoded proteins including multisubunit DNA and RNA polymer-
ases and multiple accessory factors (Ahn et al., 1990; Amegadzie 
et al., 1991; Challberg and Englund, 1979; Condit et al., 1991; Earl 
et al., 1986; Klemperer et al., 2001; McDonald et al., 1997; Moss 
et al., 1991). Functional characterization of these proteins over 
the last three decades has provided broad mechanistic insights 
into genome replication and transcription, which are of interest 
to virology and cell biology alike. While poxviruses avoid obstacles 
such as chromatin which nuclear viruses face, cytoplasmic replica-
tion means that they are also challenged by host defenses specific 
to that environment. In turn, viruses employ countermeasures to 
inactivate the host defenses which are the most significant threat. 
Recent studies have revealed that the product of the vaccinia B1R 
gene is one such countermeasure.
Analysis of temperature sensitive mutant viruses, including 
the ts2 virus, which contain a point mutation within the B1 ORF 
(Condit et al., 1983; Rempel et al., 1990; Rempel and Traktman, 
1992; Traktman et al., 1989) provided the first evidence of the es-
sential role played by B1 during the vaccinia lifecycle (Banham 
and Smith, 1992; Lin et al., 1992; Rempel and Traktman, 1992). 
Subsequent genetic and biochemical analysis of B1 revealed it to 
be a Ser/Thr kinase essential for viral DNA replication as well 
as for optimal intermediate transcription (Banham and Smith, 
1992; Kovacs et al., 2001; Lin et al., 1992), and also determined 
that the lesion found in the ts2 virus abrogates B1’s kinase activ-
ity. The vaccinia B1 protein exhibits significant homology with a 
family of eukaryotic kinases now referred to as vaccinia-related ki-
nases (VRKs) (Nezu et al., 1997; Nichols and Traktman, 2004). 
Importantly, Boyle and Traktman discovered that the cellular ki-
nase VRK1, when expressed from the ts2 genome, rescued the 
DNA replication defect exhibited by this virus (Boyle and Trakt-
man, 2004). This study suggested that B1 and VRK1 both target 
the same substrate needed to permit genome replication, and laid 
the foundation for the identification of the barrier to autointegra-
tion factor (BAF/BANF1) as a cellular substrate of B1 and VRK1 
(Wiebe and Traktman, 2007).
BAF is a highly conserved 10-kDa DNA binding protein found 
in both the cytoplasm and the nucleus of many cell types, and has 
been found to be important for cell survival in multiple model sys-
tems (Cai et al., 1998; Cox et al., 2011; Furukawa et al., 2003; 
Lee and Craigie, 1998; Margalit et al., 2005, 2007; Puente et al., 
2011; Zheng et al., 2000). Specifically, BAF is needed for survival 
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Abstract
Barrier to autointegration factor (BAF/BANF1) is a cellular DNA-binding protein found in the nucleus and 
cytoplasm. Cytoplasmic BAF binds to foreign DNA and can act as a defense against vaccinia DNA replica-
tion. To evade BAF, vaccinia expresses the B1 kinase, which phosphorylates BAF and blocks its ability to bind 
DNA. Interestingly, B1 is also needed for viral intermediate gene expression via an unknown mechanism. 
Therefore, we evaluated the impact of B1-BAF signaling on vaccinia transcription. Strikingly, the decrease in 
vaccinia transcription caused by loss of B1 can be rescued by depletion of BAF. The repressive action of BAF 
is greatest on a viral promoter, and is more modest when non-vaccinia promoters are employed, which sug-
gests BAF acts in a gene specific manner. These studies expand our understanding of the role of the B1 kinase 
during infection and provide the first evidence that BAF is a defense against viral gene expression.
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and differentiation of both human and mouse embryonic stem 
cells (Cox et al., 2011). Additionally, attempts to deplete or knock 
out BAF in Caenorhabditis elegans and Drosophila melanogas-
ter resulted in lethal phenotypes early in embryogenesis ( Furu-
kawa et al., 2003; Margalit et al., 2007). Recent data has also pro-
vided new insight of the importance of BAF in human disease. 
Specifically, a point mutation within the BAF coding region causes 
Nestor-Guillermo syndrome, a hereditary progeroid syndrome ( 
Puente et al., 2011).
Extensive in vitro biochemical and structural studies of BAF 
have advanced our understanding of BAF’s function and regula-
tion (Bradley et al., 2005; Haraguchi et al., 2001; Harris and En-
gelman, 2000; Ibrahim et al., 2011; Margalit et al., 2005; Segura-
Totten et al., 2002; Segura-Totten and Wilson, 2004; Umland et 
al., 2000). BAF binds double-stranded DNA independent of se-
quence (Lee and Craigie, 1998; Umland et al., 2000; Zheng et al., 
2000), but does not bind ssDNA, ssRNA, or dsRNA (Ibrahim et 
al., 2011; Lee and Craigie, 1998). Through its ability to homodi-
merize, BAF can cross-bridge DNA to form higher order nucleo-
protein complexes (Lee and Craigie, 1998; Zheng et al., 2000). 
Phosphorylation of BAF by either the viral B1 or cellular VRK1 
proteins strongly inhibits BAF’s ability to bind DNA, and regulates 
BAF in both the cytoplasm and nucleus (Nichols et al., 2006). 
In the nucleus, BAF interacts with LEM-domain proteins, his-
tones, and transcriptional regulators (Dechat et al., 2004; Furu-
kawa, 1999; Haraguchi et al., 2001; Lee et al., 2001; Margalit et 
al., 2005; Montes de Oca et al., 2005, 2009; Segura-Totten et al., 
2002; Segura-Totten and Wilson, 2004; Shumaker et al., 2001). 
These partners allow BAF to play an important role during nuclear 
reassembly, and likely allow BAF to modulate gene expression as 
well. In the cytoplasm BAF is capable of inhibiting viral DNA rep-
lication (Wiebe and Traktman, 2007). This host defense activity of 
BAF depends on its DNA binding and bridging properties and is 
blocked through phosphorylation in the presence of active B1 ki-
nase (Ibrahim et al., 2011).
In this manuscript, we further explore the importance of the 
B1-BAF signaling axis during poxviral infection. Specifically, we 
test the hypothesis that the action of BAF explains why B1 kinase 
is needed for intermediate transcription as well as DNA replica-
tion. We have determined that depletion of BAF from mouse L929 
cells rescues the transcriptional defect of the ts2 B1-deficient virus. 
Interestingly, the impact of BAF is greatest on the viral G8 pro-
moter as compared with other non-vaccinia promoters examined. 
Thus, our data suggests that while BAF can bind any dsDNA se-
quences, its ability to repress transcription is specific to the pro-
moter BAF is acting on. Together, these data reveal a novel prop-
erty of BAF as a transcriptional inhibitor and demonstrate that 
vaccinia is an excellent model system for future characterization of 
BAF’s function as a regulator of gene expression.
Results
The regulation of viral intermediate gene expression re-
quires the B1 kinase independently of its role in DNA 
replication
Temperature sensitive vaccinia viruses with lesions in the B1 
kinase (ts2 and ts25) display a primary block at the stage of DNA 
replication at nonpermissive temperature (Condit et al., 1983). 
The requirement for B1 at this stage is linked to its ability to in-
activate the cellular factor BAF via phosphorylation. If left un-
phosphorylated, BAF relocalizes to viral factories and impairs vi-
ral genome replication via its ability to bind and crossbridge DNA 
(Ibrahim et al., 2011; Nichols et al., 2006; Wiebe and Traktman, 
2007). Interestingly, prior to the discovery of the B1-BAF signal-
ing axis, Kovacs et al. have shown that B1 is also required for at 
least one post replicative stage in the viral life cycle. Specifically, 
using a plasmid transfection/infection approach to examine in-
termediate gene expression independent of DNA replication, it 
was discovered that intermediate promoter activity is impaired 
during infection with ts25 (Kovacs et al., 2001). However, the 
mechanism through which B1 contributes to gene expression has 
yet to be determined.
The goal of this present study was to further examine the role 
of B1 during vaccinia intermediate gene expression and test the 
hypothesis that without an active B1 kinase the cellular factor BAF 
is not only able to impede DNA replication, but viral transcription 
as well. To test this hypothesis, we first worked to confirm the role 
of B1 in intermediate gene expression as previously reported (Ko-
vacs et al., 2001). L929 fibroblasts were transfected with plasmids 
expressing firefly luciferase under the intermediate promoters 
of the G8R, A2L, I1L genes or a synthetic intermediate promoter 
based on the consensus sequence described by Yang et al. (2012). 
These cells were then infected with WT or ts2 viruses at an MOI 
of 3 and incubated at 37 °C overnight before harvesting and mea-
surement of luciferase activity. A temperature of 37 °C was chosen 
for our studies because we found that L929 cells are highly sensi-
tive to heat induced stress at 39.7 °C. As we found that multiple 
temperature-sensitive viruses retain their ts phenotype at 37 °C 
in L929 cells (see Figure 2 below), we chose to employ this tem-
perature in our studies to minimize the impact of unknown stress 
responses on the interpretation of our data. To examine viral in-
termediate gene expression independent of DNA replication, the 
nucleoside analog cytosine arabinoside (AraC) was added during 
the infection, as previous studies have shown that the expression 
of vaccinia genes from a plasmid introduced into infected cells 
does not require viral DNA replication (Keck et al., 1990; Vos and 
Stunnenberg, 1988). As shown in Figure 1A, expression from pG8-
Luciferase (pG8-Luc) is inhibited in ts2-infected cells over 200-
fold compared to WT-infected cells. This is in line with the previ-
ous observation by Kovacs et al. that the presence of a functional 
B1 kinase is necessary for the viral intermediate gene expression. 
Likewise, activation of each of the A2L, I1L, and consensus inter-
mediate promoters was significantly decreased in the ts2 infected 
cells as compared to WT infected cells, demonstrating that B1 is 
important for expression of intermediate genes in general. As the 
pG8-Luc construct exhibited the greatest fold difference between 
WT and ts2 infections, we focused on it for the remainder of our 
study to allow for the greatest sensitivity in our assays.
Next, we tested whether the defect in intermediate gene ex-
pression of ts2 can be rescued by expression of B1 from the viral 
TK locus of the ts2 virus. Using recombinant ts2 viruses, Boyle and 
Traktman demonstrated that expression of B1 from the TK locus 
of the ts2 genome rescues the DNA replication defect of this vi-
rus (Boyle and Traktman, 2004). Using the same virus, we veri-
fied that in L929 cells the expression of B1 from the ts2 virus res-
cued viral yield compared to ts2 alone at either low or high MOI 
(Figure 1C), as was previously observed in BSC40 cells (Boyle and 
Traktman, 2004). We also found that luciferase activity measured 
in ts2/B1 was 50-fold higher than that found in ts2-infected cells 
(Figure 1B). These results support the role of the B1 kinase during 
viral intermediate gene expression, and demonstrate that expres-
sion of B1 from the ts2 genome can both rescue viral yield and en-
hance viral intermediate gene expression in L929 cells.
BAF affects viral intermediate gene expression in a B1 
dependent manner
The above data indicate that the B1 kinase is required not only for 
DNA replication, but intermediate gene expression as well. To de-
termine whether B1 is unique in functioning at both of these stages 
of the viral lifecycle, we examined whether intermediate gene ex-
pression was decreased during infection with other ts viruses dis-
playing blocks in DNA replication. Specifically, two ts mutants 
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with DNA replication defects were employed: ts42 virus carries 
a mutation in the viral catalytic DNA polymerase (E9) (McDon-
ald and Traktman, 1994; Sridhar and Condit, 1983) and ts24 car-
ries a mutation in the D5 primase/helicase protein (De Silva et al., 
2007, 2009; Evans and Traktman, 1992; Evans et al., 1995). First, 
we verified that viral DNA replication was impaired at 37 °C dur-
ing infection with these viruses. L929 cells were infected (MOI=3) 
with WT, ts2, ts42, or ts24 and lysates were collected at 0.5 and 
24 hpi for DNA quantification using quantitative PCR. As shown 
in Figure 2A, while during WT infection viral DNA increased more 
than 150-fold in 24 h, ts2 DNA was increased only ~3-fold com-
pared to input and no increase in DNA was detected during ts42 
and ts24 infections. These data demonstrate that in L929 cells, 
37 °C is a nonpermissive temperature for each of these mutant 
viruses.
Next, these viruses were used to begin our examination of the 
role of BAF in intermediate gene expression. First, we transduced 
L929 cells with replication-incompetent lentiviral vectors express-
ing either a BAF-specific or control (CTRL) shRNA. Immunob-
lot analysis of lysates from these cells revealed that expression of 
BAF in L929-shBAF cells is decreased to 15–20% compared to 
that from the untransduced L929 cells, while no impact on BAF 
expression was detectable in the shCTRL cells (Figure 2B). Next, 
L929-Control and -shBAF cells were transfected with pG8-Luc, 
then infected with WT, ts2, ts42 or ts24 viruses (MOI=3) in the 
presence of AraC for 16–20 h prior to harvest and measurement 
of luciferase activity. In L929-shControl cells (Figure 2C, left), we 
found that pG8-Luc reporter activity in cells infected with ts24 
was identical to WT infection, and ts42 were only slightly (2.5-
fold) reduced. This was in clear contrast to pG8-Luc activity dur-
ing ts2 infection, which was more than two orders of magnitude 
lower. This result indicates that E9 and D5 do not affect interme-
diate gene expression and that the importance of B1 at this stage is 
not common among viral DNA replication proteins.
Next, the same transfection/infection protocol was performed 
in L929-shBAF cells where BAF expression is stably depleted. In-
terestingly, in these cells reporter gene expression was enhanced 
to at least some degree regardless of the virus used (Figure 2C). 
Luciferase activity in WT, ts42, and ts24 infected L929-shBAF 
cells was 2–3 folds greater than that observed for each of those vi-
ruses in L929-shControl cells (Figure 2D). Strikingly however, lu-
ciferase activity in ts2 infected L929-shBAF cells was close to 40-
fold greater than that in L929-shControl cells (Figure 2C and D). 
This specific rescue of ts2-mediated intermediate gene expres-
sion in BAF depleted cells suggests that the B1-BAF signaling axis 
is important at this stage of the life cycle as well as during DNA 
replication.
Depletion of B1 during WT vaccinia infection also im-
pedes transcription in a BAF-dependent manner
To further characterize the role of B1 during intermediate gene 
regulation, we examined whether siRNA-mediated depletion of 
B1 would yield results similar to those obtained above with the ts2 
Figure 1. The ts2 defect in interme-
diate transcription is observed on 
multiple promoters and is rescued 
by B1 expression in L929 cells. (A and 
B) L929 cells were transfected with the re-
porter construct shown for 7 h, then in-
fected at 37 °C with WT, ts2, or ts2/B1 
as indicated (MOI=3) in the presence of 
50 μM AraC. Lysates were prepared at 16 h 
after infection and assayed for luciferase 
activity. RLU shown is normalized to to-
tal protein measured by BCA assay. Data 
were obtained from three independent ex-
periments performed in triplicate wells. 
Data from a representative experiment is 
shown. Error bars represent the standard 
deviation. (C) L929 cells were infected 
with WT, ts2, or ts2/B1 at MOI=0.1 or 
MOI=5 for 24 h at 37 °C. After lysates were 
collected virus yield was determined by a 
plaque titration on monolayers of BSC40 
cells at 32 °C. Data were obtained from 
triplicate experiments, and standard devia-
tion is presented by the error bars. (*** in-
dicates a p-value <0.05).
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virus. To establish a method for depletion B1 mRNA, L929 cells 
were transfected with 100 nM of B1-specific or control siRNA for 
24 h, followed by an infection with WT virus at MOI=3 at 37 C for 
4 h. Two B1-specific siRNA were tested. Lysates were collected and 
RNA extracted for subsequent qPCR using primers specific to the 
B1 ORF. Based on RT-qPCR results (Figure 3A), the accumulation 
of B1-specific transcripts was substantially reduced in siB1-pre-
treated cells compared non-treated cells. The decrease in B1-spe-
cific transcripts was 90% with siB1-1 and 70% with siB1-2. Due to 
the greater depletion by siB1-1, we selected that siRNA for use in 
subsequent studies.
To determine whether depletion of B1 results in diminished in-
termediate gene expression, L929 were transfected with siB1 or si-
Control for 12 h, then transfected with pG8-luc for 7 h before in-
fecting with WT vaccinia in the presence of AraC. Cells transfected 
only with pG8-Luc and infected with ts2+AraC were included for 
comparison purposes. To simultaneously investigate the involve-
ment of BAF in these studies, both L929-shControl and L929-sh-
BAF cells were employed. In L929-shControl, we found that de-
pletion of B1 leads to a substantial decrease in the activity of the 
reporter gene when compared to siControl-transfected cells or 
cells not treated with any siRNA (Figure 3B). Specifically, we ob-
served an average decrease of ~40-fold in luciferase activity, 
bringing the reporter activity to a level very similar to that ob-
tained during the ts2 infection. In L929-shBAF cells, the depletion 
of BAF was able to rescue the loss of intermediate gene expression 
caused by siB1 treatment as well as during ts2 infection. As in Fig-
ure 2C and D, the fact that the loss of BAF specifically enhances 
gene expression when B1 has been depleted further supports our 
model that B1 is needed to repress the inhibitory activity of BAF.
BAF immunoprecipitates pG8-Luc DNA and depletion of 
BAF rescues viral intermediate gene expression at the 
transcriptional level
Although we have previously shown that BAF relocalizes to trans-
fected dsDNA by immunofluorescence (Ibrahim et al., 2011) and 
other studies have also shown BAF’s DNA-binding capability in vi-
tro via biochemical and structural studies (Bradley et al., 2005; 
Cai et al., 1998; Umland et al., 2000; Zheng et al., 2000), BAF’s 
direct interaction with DNA in an intact cell has yet to be dem-
onstrated by co-immunoprecipitation. Therefore, to validate that 
BAF impairs gene expression through its direct DNA-binding ac-
tivity, we performed chromatin immunoprecipitation analysis in 
L929 cells stably expressing MCS empty vector (control) or FLAG-
BAF. Cells were transfected with 150 ng pG8-Luc plasmid for 24 h 
followed by immunoprecipitation of BAF-DNA complexes. Bound 
pG8-Luc DNA was analyzed by qPCR analysis using a pG8-Luc-
specific primer set which flanks the G8 promoter region. In FLAG-
BAF-expressing cells, we observed an increase in pG8-Luc DNA 
binding compared to control cells. Specifically, while the plas-
mid DNA harvested for the input samples was similar between the 
MCS and Flag-BAF expressing cells, following immunoprecipita-
tion the average difference in Ct was 5.3 Ct lower (Supp Figure 2) 
in the Flag-BAF cells and fold enrichment ~40 fold higher than 
the control cells (Figure 4A). As all previous studies of BAF have 
shown that BAF binds dsDNA in a sequence independent man-
ner we were curious as to whether BAF is preferentially binding 
Figure 2. The defect in intermediate 
transcription is specific to ts2 and is 
rescued by depletion of BAF. (A) DNA 
replication assays. Total DNA was isolated 
at 30 min and 24 h after infection (MOI=3) 
with WT, ts2, ts42, or ts24 at 37 °C, then 
quantified by qPCR. Data was obtained from 
two independent experiments, PCR ampli-
fied in duplicate. Data is shown as a fold 
difference compared to the WT sample at 
0.5 hpi. Error bars represent standard devi-
ation. (B) Immunoblot analysis of BAF ex-
pression in L929 cells stably depleted of BAF 
using specific shRNA. Lysates from equiva-
lent numbers of cells were collected and an-
alyzed using antibody against BAF. The total 
amounts of BAF in each lane were quantified 
using a Bio-Rad Chemidoc XRS instrument. 
GAPDH level was used as loading control. 
(C) L929 cells stably expressing shBAF or 
shControl were transfected with pG8-Lucif-
erase for 7 h, then infected at 37 °C with WT, 
ts2, ts42 or ts24 at MOI=3 in the presence of 
50 μM AraC. Lysates were prepared at 16 h 
after infection and assayed for luciferase ac-
tivity. RLU shown is normalized to total pro-
tein measured by BCA assay. Data were ob-
tained from three independent experiments 
performed in triplicate wells. Data from a 
representative experiment is shown. Error 
bars represent standard deviation. (D) Data 
from the luciferase expression shown in (C) 
was replotted as a fold difference between the 
shControl and shBAF cell lines for each virus. 
(*** indicates a p-value <0.05).
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the G8 promoter. Therefore, in addition to G8 promoter-specific 
primers, we also utilized primers specific to the Neomycin resis-
tance gene on the opposite site of the plasmid and the cellular 
beta-actin gene. We found that the Neo region of the plasmid and 
beta-actin gene were immunoprecipitated with an efficiency al-
most equal to the G8 promoter (Figure 4B and C). These data sup-
port a model in which BAF directly interacts with many, if not all, 
regions of the plasmid construct during its impairment of gene ex-
pression. Such a model would also be consistent with previous in 
vitro DNA binding data and structural studies demonstrating that 
BAF binds dsDNA in a sequence independent manner.
Kovacs et al. have previously shown that B1 impacts interme-
diate gene expression at the level of transcription (Kovacs et al., 
2001). To confirm and extend those results, we sought to deter-
mine whether B1’s impact on transcript levels is BAF-dependent. 
For these studies, L929-shControl and shBAF cells were trans-
fected with increasing amounts of pG8-Luc plasmid, then infected 
with WT or ts2 virus (MOI=3) and incubated at 37 °C in the pres-
ence of AraC. At 4 hpi, lysates were collected and RNA extracted 
for RT-qPCR analysis using a luciferase-specific primer/probe set. 
In L929-shControl cells, the accumulation of transcripts in ts2 in-
fected cells was reduced compared to WT infected cells (Figure 
4D). This difference between ts2 and WT transcription was ob-
served at all plasmid concentrations, but was greatest at lower 
plasmid amounts. As higher amount of plasmids were used, the 
difference in transcripts between WT and ts2 infection shrinks. 
Next, upon examining the impact of BAF depletion on transcripts 
synthesized under the viral G8 promoter, we found that ts2-medi-
ated transcription was greater in L929-shBAF cells than in L929-
shControl cells. Most significantly, when using 10 ng of DNA there 
was a >10-fold increase in transcript accumulation in L929-shBAF 
cell as compared to ts2-infected L929-shControl cells. Together, 
these data are consistent with our model that BAF can be a repres-
sor of viral gene expression at the transcriptional level if B1 is not 
present to phosphorylate it.
The impact of BAF on gene expression is promoter 
dependent
In light of the ability of BAF to bind to dsDNA in a sequence inde-
pendent manner, we hypothesized that it may be capable of impact-
ing transcription of genes other than the pG8-Luc reporter con-
struct. To address this hypothesis, we began by asking (1) whether 
the transcriptional role of BAF during gene expression is promoter 
dependent and (2) whether the effect of B1 is also promoter depen-
dent. For these studies, plasmids were employed that express firefly 
luciferase under a T7, CMV or a ‘minimal’ (minP) promoter, which 
contains primarily a TATA box. T7-Luc was selected to be used in 
conjunction with the recombinant vaccinia virus vTF7.3, which ex-
presses a wild-type B1 protein as well as the T7 polymerase. Thus, 
transcription from the T7-Luc/vTF7.3 system will allow us to mea-
sure reporter gene expression from transcription in the cytoplasm, 
but in a manner independent of the vaccinia RNA polymerase and 
transcription factors. The CMV-Luc and minP-Luc constructs con-
tain a strong and weak promoter, respectively, and are both acti-
vated by cellular factors and therefore result in nuclear transcrip-
tion. As BAF is present in both the cytoplasm and nucleus, its 
impact on transcription in both locations is of interest.
We began by examining the impact of the B1-BAF axis on T7-
mediated gene expression. L929-shBAF and shControl cells were 
transfected as indicated with siB1 or siControl, then transfected 
with T7-luciferase, and later infected with vTF7.3 virus at MOI=3 
in the presence of AraC for an additional 16 h before harvest. As 
shown in Figure 5A (left), siB1 treatment of L929-shControl cells 
infected with vTF7.3 resulted in only a minor (2.5-fold) reduction 
in T7-Luc reporter gene expression, contrary to what was observed 
for pG8-Luc expression during WT infection (Figure 3). When the 
same transfection / infection study using T7-Luc was performed 
in L929-shBAF cells, transcription activity rose modestly and was 
similar in all cases regardless of B1 siRNA treatment regimen. 
While these data suggest the B1-BAF axis contribute somewhat to 
the level of T7-driven reporter activity observed, the magnitude of 
their contribution is far less than what was observed when study-
ing the pG8-Luc reporter.
Next, we wanted to test whether the depletion of BAF can en-
hance the expression of a reporter gene under a promoter tran-
scribed in the nucleus. L929-shControl and shBAF were transfected 
with two different amount of CMV-Luc (immediate early promoter) 
or minP-Luc plasmid for 24 h at 37 °C; then lysates were collected 
and analyzed for luciferase activity. As shown in Figure 5B, at both 
DNA concentrations minP promoter-mediated luciferase expres-
sion was enhanced only 2-fold in L929-shBAF cells, and the CMV 
promoter-mediated luciferase expression (Figure 5C) was simi-
lar regardless of BAF level of expression. Based on the contrast be-
Figure 3. Depletion of B1 impairs intermediate transcription 
following WT virus infection, and can be rescued by BAF de-
pletion. (A) L-929 cells were transfected with 100 nM of siRNA si-
Control, siB1R-1, or siB1R-2. At 24 h post transfection, cells were in-
fected with WT virus at a MOI of 3 and total RNA harvested at 4 hpi. 
Following reverse transcription, cDNA was quantified by qPCR. (B) 
L929 stably expressing shBAF or shControl were transfected with 
100 nM siRNA specific to B1 kinase (siB1-1) or siControl for 12 h, and 
then transfected with pG8-Luciferase for 7 h, then infected at 37 °C 
with WT virus at MOI=3 in the presence of 50 μM AraC. An infection 
of L929 with ts2 at MOI=3 in the presence of AraC at 37 °C was also 
performed. Lysates were prepared at 12 h after infection and assayed 
for luciferase activity, and RLU normalized to protein level. Data were 
obtained from three independent experiments performed in triplicate 
wells. Data from a representative experiment is shown. Error bars rep-
resent standard deviation. (*** indicates a p-value <0.05).
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tween these data with the T7, CMV and minP promoters and the 
earlier data using the G8 promoter, it is evident that the B1-BAF 
axis affects transcription in a gene specific manner. In our view, this 
specificity may be due to differences in transcription factors and 
polymerases in play and/or subcellular localization of the DNA in 
question and is discussed in more detail below.
Discussion
Vaccinia virus possesses multiple sophisticated mechanisms to 
manipulate cellular signaling pathways and subvert host defenses 
(Bowie and Haga, 2005; Moss and Shisler, 2001; Perdiguero and 
Esteban, 2009). Studies on vaccinia-host interactions continue to 
provide novel insights into the mechanisms employed by both vi-
rus and host alike to achieve their respective goals during the course 
of an infection. For example, the vaccinia B1 Ser/Thr kinase phos-
phorylates the cellular factor BAF, which leads to the potent inhi-
bition of BAF’s ability to bind and crossbridge viral DNA (Ibrahim 
et al., 2011; Wiebe and Traktman, 2007). VRK1, a cellular homo-
log of B1, targets BAF on the same residues as B1 (Nichols et al., 
2006). It is now known that the VRK1-BAF axis plays an impor-
tant role in mitotic regulation (reviewed in Valbuena et al., 2011), 
while the B1-BAF axis is needed for viral DNA replication (Ibrahim 
et al., 2011; Wiebe and Traktman, 2007). Importantly, these stud-
ies revealed a novel function for BAF as an antiviral effector capa-
ble of targeting vaccinia DNA in the cytoplasm. Currently, much re-
mains to be learned about the contributions of the B1 kinase to the 
viral lifecycle and specifically whether its phosphorylation of BAF is 
needed to promote more than just viral DNA replication.
The requirement of B1 for viral DNA replication, which itself is 
needed for intermediate and late gene expression, is an obstacle to 
the study of B1’s contribution to processes beyond DNA replication. 
Figure 4. BAF immunoprecipitates 
pG8-Luc DNA in L929 cells and de-
pletion of BAF rescues viral inter-
mediate gene expression at the tran-
scriptional level. (A) ChIP assays were 
performed to determine the binding of 
BAF to DNA. L929 cells stably express-
ing MCS plasmid (control) or 3xFlag-BAF 
were transfected with 150 ng pG8-lucif-
erase plasmid for 24 h. Following fixation 
and sonication, BAF-DNA complex was 
immunoprecipitated using anti-FLAG anti-
body and analyzed by quantitative PCR us-
ing primers flanking the G8 promoter (A) 
or Neomycin resistance gene (B) of pG8-
Luc DNA or the beta-actin cellular gene 
(C). Data shown is a representative from 
three independent experiments, each per-
formed in duplicate. Error bars represent 
standard deviation. Data from the Raw Ct 
values (shown in Figure S2) was plotted as 
fold enrichment relative to MCS. (D) L929 
cells stably expressing shBAF or shControl 
were transfected with 10, 100, and 500 ng 
of pG8-luciferase for 7 h, then infected 
with 37 °C with WT or ts2 at MOI=3 in the 
presence of AraC. Lysates were collected 
for RNA extraction and luciferase tran-
scripts quantified by RT-qPCR. (*** indi-
cates a p-value <0.05).
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However, as reported by Kovacs et al. (2001), by using plasmid re-
porters containing viral promoters to avoid the need for genome 
replication, B1 was indeed found to be needed beyond DNA repli-
cation (Kovacs et al., 2001). However, the mechanism underlying 
B1’s contribution to gene expression was not fully defined. There-
fore, in light of the importance of the B1-BAF axis for DNA rep-
lication, herein we examined whether B1 was acting through this 
same pathway to facilitate intermediate gene expression. As ex-
pected, the B1-deficient ts2 virus was only capable of activating the 
luciferase reporter gene under the G8R promoter to <1% to that of 
the WT virus in L929 cells (Figure 1). The ts2 virus also exhibited 
a marked reduction of expression from three other promoters in 
this study, demonstrating that B1’s role in transcription likely ex-
tends to intermediate gene expression in general. A reduction in 
ts2-driven reporter activation as compared to WT virus was also 
observed in other cell types including CV1, U2OS, and BSC40 cells 
(Figure S1A). The fact that L929 cells display the greatest sensitiv-
ity in this assay was also found by Kovacs et al., and is the reason 
why they were employed for the remainder of the study. However, 
it is interesting to note that all of these cell lines express similar 
amounts of BAF protein (Figure S1B) indicating that either the 
ts2-B1 protein or BAF exhibits cell type specific activity. Efforts to 
tease out the mechanisms underlying these cell type specific dif-
ferences is currently underway.
To directly test BAF’s involvement in the transcriptional down-
regulation seen during ts2 infection we constructed L929 cells 
stably depleted of BAF and performed luciferase reporter assays 
in those cells (Figure 2). Strikingly, cells with decreased levels of 
BAF exhibited a 40-fold increase in ts2-mediated gene expres-
sion as compared to control L929 cells (Figure 2D). While it is in-
teresting to note that the other viruses tested in this study (WT, 
ts42, and ts24) also exhibited modestly increased reporter activa-
tion, the fact that ts2 was more dramatically affected than other 
viruses demonstrates that the B1-BAF axis impacts expression of 
the reporter gene. This conclusion is also supported by our com-
plementary data that siRNA-mediated depletion of B1 from WT vi-
rus leads to a decrease in reporter activation which can be rescued 
by the depletion of BAF (Figure 3B). Together, these data strongly 
suggest that in the absence of the B1 kinase, BAF is capable of im-
pairing viral gene expression.
Finally, we have made progress towards determining the mech-
anism underlying BAF’s impact on viral gene expression. First, 
we demonstrated that multiple regions of the plasmid co-immu-
noprecipitates with BAF, supporting a model in which BAF binds 
foreign DNA in a sequence independent manner, including inter-
action with the promoter region of the reporter gene. Second, we 
directly tested whether BAF was affecting transcription of the re-
porter gene by measuring luciferase transcript accumulation dur-
ing WT and ts2 infection. Using RT-qPCR, we observed that de-
creased transcript levels observed during ts2 infection could be 
rescued by BAF depletion, indicating that BAF functions at the 
level of gene transcription. The specificity of BAF’s action against 
transcription was also examined using promoter-reporter con-
structs able to be expressed independently of the vaccinia RNA 
polymerase. Interestingly, both BAF and B1 depletions had little 
impact on a reporter under a T7 promoter during infection with 
vTF7.3, which expresses the T7 polymerase. Similarly, BAF deple-
tion had little if any impact on either minP or CMV driven reporter 
gene expression, both of which are promoters responsive to RNA 
polymerase II and cellular transcription factors. Together, these 
results provide the first evidence that BAF can function as a gene-
dependent inhibitor of transcription, which can itself be inacti-
vated by the B1 kinase.
In regard to the mechanism of BAF’s inhibition of viral gene ex-
pression, previous studies have shown that BAF’s ability to block vi-
ral DNA replication requires its DNA binding and dimerization ac-
tivity (Ibrahim et al., 2011). These properties allow BAF to bind 
and crossbridge/aggregate DNA (Bradley et al., 2005; Skoko et 
al., 2009; Zheng et al., 2000), and also likely allow BAF to impair 
transcription in the absence of B1. Precedent for this model can be 
Figure 5. The role of B1 kinase and BAF in viral intermedi-
ate gene expression is promoter dependent. (A) L929 stably ex-
pressing shBAF or shControl were transfected with siRNA specific to 
B1 kinase (siB1-1) or siControl for 12 h, and then transfected with 1 ng 
of T7-Luciferase for 7 hr, then infected with 37 °C with Wt-VTF7.3 at 
MOI=3 in the presence of AraC. Lysates were prepared at 12 h after in-
fection and assayed for luciferase activity, with RLU shown normalized 
to protein level. (B and C) L929 stably expressing shBAF or shCon-
trol were transfected with the indicated amounts of minP-Luc (B) or 
CMV-Luc (C). Lysates were prepared at 24 h after transfection and as-
sayed for luciferase activity, with RLU shown normalized to protein 
level. For all graphs, data were obtained from three independent ex-
periments performed in triplicate wells. Data from a representative ex-
periment is shown. Error bars represent standard deviation. (*** indi-
cates a p-value <0.05).
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found in prokaryotes, where DNA crossbridging by dimeric proteins 
such as H-NS is known to be a potent transcriptional silencer of for-
eign DNA (Lucchini et al., 2006). Interestingly, the potency of si-
lencing due to H-NS binding is a function of the DNA binding affin-
ity or other attributes of the transcription factors attempting to gain 
access to the promoter bound by H-NS (Navarre et al., 2006, 2007), 
consistent with a model in which the competition of repressor and 
activator proteins determine the level of gene activation.
We posit that if BAF functions via a similar mechanism to 
H-NS and is attempting to compete for DNA binding with tran-
scriptional activators it may, in part, explain the promoter-spe-
cific repression we are observing. Following this logic, in the case 
of the vaccinia promoters, the presence of BAF may be sufficient 
to hinder recruitment of some of the activators found to contrib-
ute to vaccinia intermediate transcription. For example, the action 
of viral proteins such as A8 and A23 (Sanz and Moss, 1999) as well 
as cellular factors including G3BP/p137 (Katsafanas and Moss, 
2004), TBP (Knutson et al., 2006), and Yin-Yang 1 (YY1) (Broyles 
et al., 1999; Knutson et al., 2009) have been linked to intermedi-
ate transcription and their access to the promoter may be affected 
by BAF. In contrast, the fact that gene expression from the T7, 
minP, and CMV promoters is similar in the presence or absence 
of BAF suggests that binding of the transcription factors and / or 
the polymerases to those promoters may not be greatly impeded 
by BAF. Additionally, as the minP and CMV promoters are tran-
scribed in the nucleus, BAF’s activity may be regulated differently 
in that environment (such as by the nuclear kinase VRK1), thus re-
ducing BAF’s ability to repress foreign DNA. This possibility might 
also explain why we have found that the beta-actin gene could be 
co-immunoprecipitated with BAF (Figure 4C), while beta-actin 
transcript levels remain unchanged in control or BAF-depleted 
cells (data not shown). Future work to determine the relative con-
tribution of each of these possible regulatory mechanisms will be 
of great interest.
Finally, we would be remiss if we did not point out that in each 
of our experiments using L929-shBAF cells, the depletion of BAF 
never led to a complete recovery of the transcriptional activity lost 
due to impairment of the B1 kinase. We would suggest two pos-
sible explanations for these observations. First, while BAF deple-
tion is significant, it is still incomplete. The remaining BAF may 
be capable of inhibiting intermediate gene expression. Secondly, 
we posit that B1 may have substrates other than BAF that are also 
needed for optimal transcription, which are mediating this differ-
ence in gene expression. In this regard one possible candidate is 
the viral H5 protein, which is known to be phosphorylated by B1 
and has been linked to transcriptional regulation in other stud-
ies (Black et al., 1998; Brown et al., 2000; D’Costa et al., 2008, 
2010; Kovacs and Moss, 1996). Additional studies will be needed 
to distinguish between these two possibilities.
In summary, these studies reveal that the B1-BAF signaling 
axis impacts both DNA replication and intermediate gene expres-
sion. Our observations demonstrate for the first time that BAF 
can act as a transcriptional repressor and provide the first evi-
dence that this inhibitory activity can be regulated by phosphor-
ylation of BAF. Although this study focuses on vaccinia transcrip-
tion in the cytoplasm, the fact that a large fraction of BAF exists in 
the nucleus and is targeted there by VRK1, suggest that post-trans-
lational regulation of BAF probably has implications for cellular 
gene expression as well.
Materials and Methods
Cell culture, transfection and infection
All chemicals were purchased from Fisher Scientific or Sigma-Al-
drich unless otherwise stated. African green monkey BSC40 kid-
ney epithelial cells, CV1, U2OS, and mouse fibroblast L929 cells 
were obtained from ATCC and maintained in Dulbecco’s modified 
Eagle’s medium (DMEM) supplemented with 10% fetal bovine se-
rum (FBS; Atlanta Biologicals) and penicillin-streptomycin and 
incubated at 37 °C in a 5% CO2 atmosphere.
Plasmids
For transfection experiments performed in the absence of vaccinia 
infection, two plasmids expressing firefly luciferase were used: 
CMV-Luc expresses luciferase under the CMV immediate early 
enhancer promoter (pGL4.51[luc2/CMV/Neo], Catalog# E1320), 
and minP-Luc expresses luciferase under a minimal promoter 
containing only a TATA box (pGL4.26[luc2/min/Hygro], Cata-
log# E8441). For transfection-infection experiments, pG8-lucifer-
ase expresses luciferase under the viral intermediate G8 promoter 
(a generous gift from B. Moss, NIAID, Bethesda, MD), and T7-lu-
ciferase (Promega) were used.
Plasmids containing A2, I1 and Consensus Intermediate pro-
moter sequences upstream of the firefly luciferase gene were con-
structed as follows. PCR was performed using pG8-Luciferase 
plasmid as a template and primers designed to include sequences 
previously published of I1, A2 and Consensus promoters (Bal-
dick et al., 1992; Knutson et al., 2006; Yang et al., 2012). All three 
promoters (in bold) were placed upstream of 18 bp homologous 
to the 5′ end of firefly luciferase gene (in italics). Non-viral se-
quences including three nucleotides followed by EcoRI restriction 
sites were placed upstream of the promoter sequences (in lower 
case). The upstream primers are A2L-Luc (5′ccggaattcGCAAC-
GTCTAGAAATAAAATGTTTTTATATAAAAatggaagatgc-
caaaaac-3′), I1L-Luc (5′-ccggaattcTTTGTATTTAAAAGTT-
GTTTGGTGAACTTAAATGGCagacgccaaaaacataaag-3′) and 
Consensus-Luc (5′-ccggaattcTAATATATTTAAAATAAAAAT-
TAATATTATAAAatggaagatgccaaaaac-3′). The downstream 
primer, Universal-Luc-3′ (5′-caggaattcttacacggcgatcttTc-3′), is 
homologous to the 3′-end of the firefly luciferase ORF, and con-
tains an EcoRI site (lowercase) as well. PCR products amplified 
using these primers were cloned into the pCRII-TOPO plasmid 
(Invitrogen) using the EcoRI restriction and promoter identity 
verified following DNA sequencing.
Viruses
The following viruses were used: wild-type vaccinia virus (WR 
strain), the B1-deficient ts2 virus (Condit et al., 1983; Rempel et 
al., 1990; Rempel and Traktman, 1992), and vTF7.3 (Fuerst et al., 
1986). Recombinant virus ts2/B1 (Boyle and Traktman, 2004) was 
provided by Dr. Traktman (Medical College of Wisconsin). Viruses 
ts42 (E9 mutant) and ts24 (D5 mutant) were gifts from Dr. Rich 
Condit (University of Florida). Stocks of all viruses were purified 
from cytoplasmic lysates of infected BSC40 cells by ultracentrifu-
gation through 36% sucrose; and quantified by plaque assay titra-
tion on BSC40 cells.
Production of cells stably overexpressing BAF
The stable overexpression of BAF in L929 cells was performed by 
using a lentivirus expressing 3XFlag-BAF (plasmids were a kind 
gift from Dr. Paula Traktman (Molitor and Traktman, 2013)). Spe-
cifically, 293 T cells were transfected with pHM-3XFlag-BAF or 
pHM-MCS plasmid (Mostoslavsky et al., 2006; Ory et al., 1996) 
with a combination of viral packaging plasmids pVSV-G, pTat, 
pREV and pGag/Pol. The next day, media was replaced with 
fresh media containing 5 mM Sodium Butyrate. Eight hours later 
fresh media containing 10 mM HEPES pH7.4 was added for addi-
tional 12 h. Next, media containing lentivirus was filtered through 
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a 0.45 μm sterile filter, and polybrene (8 μg/ml) was added and 
stored at −80 °C. For transduction, L929 cells were seeded in 
35 mm dishes at 1×106 per well. The next day, medium was re-
placed with 1 mL of lentivirus supernatant. After 24 h, medium 
was replaced with fresh media for additional 24 h. Cells were then 
grown in media containing 200 μg/ml of hygromycin to select for 
stable lentiviral integration.
Production of cells stably depleted of BAF
The stable depletion of BAF was performed using a lentivirus ex-
pressing a BAF-specific short hairpin RNA (shRNA) or con-
trol (scrambled) shRNA as previously described (Ibrahim et al., 
2011), with the exception that transduced cells were selected with 
15 ug/ml of puromycin. To express shRNA specific to murine BAF 
mRNA, the primers mBAFsense (5′-TGGCTTATGTGGTCCTTG-
GCTTCAAGAGAGCCAAGGACCACATAAGCCTTTTTGGAAAC-3′) 
and mBAFantisense (5′-TCGAGTTTCCAAAAAGGCTTATGTG-
GTCCTTGGCTCTCTTGAAGCCAAGGACCACATAAGCCA-3′) 
were annealed and cloned into the pLL3.7 as previously described 
(Wiebe and Traktman, 2007).
Luciferase assays
Transfection-Infection experiments: L929 cells seeded at 2×105 
per well of a 12-well plate were transfected using Lipofectamine 
2000 (Invitrogen) with 10 ng of pG8-Luc DNA per well. The plas-
mid-Lipofectamine transfection complexes were prepared as fol-
lows:130 ng of pG8-luciferase and 1 μl of Lipofectamine 2000 
were combined in 2.3 mL of DMEM; and 200 μl of the transfec-
tion mixture was used per well. Cells were incubated at 37 °C in a 
5% CO2 atmosphere for 7 h to allow for plasmid introduction into 
the cells, which were then infected with vaccinia virus at a mul-
tiplicity of infection (MOI) of 3 in media containing 50 μM AraC 
and placed back in the incubator for additional 18 h. Cells were 
then washed twice with phosphate-buffered saline(PBS) (10 mM 
Na2HPO4−7H2O, 1 mM KH2PO4, 2 mM KCl, 140 mM NaCl [pH 
7.4]), then lysed in 300 μl of 1X Reporter Lysis buffer (Promega) 
by two freeze-thaw cycles. The luciferase activity was measured 
using 50 μl of lysate for 100 μl of luciferase assay substrate buffer 
in a Berthold multiwell Luminometer.
Transfection alone: L929 cells were seeded at 2×105 per well of a 
12-well plate, and the next day they were transfected using Lipo-
fectamine 2000 (2 μl per μg DNA; Invitrogen) with CMV-Luc or 
minP-luciferase for additional 12 h. Cells were washed twice with 
PBS, and then lysed with 300 μl of 1X Reporter Lysis buffer (Pro-
mega), and freeze-thaw twice. The luciferase activity was mea-
sured using 50 μl of lysate and 100 μl of luciferase assay substrate 
buffer in a Berthold multiwell Luminometer. Firefly luciferase ex-
pression was normalized to relative total protein level in each ly-
sate. Protein level in each lysate was quantified by BCA protein as-
say (Thermo Scientific).
Immunoblot analysis
L929 and L929 stably expressing specific shRNA were freshly col-
lected in 300 μl of SDS sample buffer (100 mM Tris pH6.8, 2% 
β-mercaptoethanol, 2% SDS, 32.5% glycerol, bromophenol blue) 
supplemented with 10 units of Benzonase. Lysate volume equiv-
alent to 105 cells were subjected to SDS-polyacrylamide gel elec-
trophoresis (PAGE) on a 18% gel, transferred to PVDF, and incu-
bated with primary against BAF (Wiebe and Traktman, 2007), and 
rabbit secondary antibodies. Blots were developed with chemilu-
minescent reagents, and quantified by a Bio-Rad Chemidoc XRS 
instrument to verify that BAF expression had been depleted >85%.
B1 siRNA transfection/infection
B1-specific and control siRNAs were designed and ordered from 
Dharmacon. The B1-1siRNA sense sequence is 5′–CAAUAUG-
CACCUAGAGAAUUU-3′ and the B1-2 siRNA sense sequence 
is 5′–GCCCAAAGCUAACGGAUCAUU-3′. The siControl sense 
strand sequence is 5′–CAGUCGCGUUUGCGACUGGUU-3′. L-929 
cells were transfected with 100 nM of siRNA Control, siB1R-1, or 
siB1R-2 using RNAimax (Life Technologies) as per manufacturer’s 
protocol. 16–24 h post transfection cells were infected with WT vi-
rus at an MOI of 3 and harvested for B1R mRNA at 4 hpi. RNA was 
extracted using TRIzol reagent, purified with Aurum Total RNA 
mini kit (Biorad), reverse transcribed to generate cDNA (Applied 
Biosystems, High Capacity cDNA Reverse Transcription Kit), and 
treated with 0.5 μg/ml RNase A prior to qPCR analysis.
qPCR
qPCR performed on B1R cDNA was done using TaqMan mas-
ter mix (Applied Biosystems) and 900 nM of primers B1R F 
(5′-AATCAATGGGTCGTTGGACCAT-3′) and B1R R (5′-AATA-
CATCATTTTTATCTCGGGTTTCGATTGC-3′), and 250 nM B1R 
probe (5′–56-FAM/AG GTG CAG ATC TAG ATG CGG TGA TCA 
/3IABkFQ-3′), specific to the vaccinia virus B1R gene. To mea-
sure viral DNA replication, DNA was extracted from the cells 
with the QIAamp DNA Blood Mini Kit (Qiagen) and treated with 
5 μg/ml RNase A. Viral DNA replication was quantified using 
SYBR green PCR mix (Applied Biosystems) with primers specific 
to the vaccinia virus HA gene at a concentration of 900 nM each 
(HA F: 5′-CATCATCTGGAATTGTCACTA CTAAA-3′ and HA R: 
5′-ACGGCCGACAATATAATTAATGC-3′).
ChIP Assays
L929 cells (107) stably expressing specific shRNA were transfected 
with 150 ng pG8-Luc plasmid for 24 h. Cells were cross-linked 
with 1% formaldehyde for 10 min at room temperature followed by 
quenching with 0.75% glycine. Cell lysis was done using FA lysis 
buffer (50 mM HEPES-KOH pH 7.5, 140 mM NaCl, 1 mM EDTA 
pH 8, 1% TritonX-100, 0.1% sodium deoxycholate, 0.1% SDS, and 
protease inhibitor (Complete, Roche)). Lysates were sonicated 
with Misonix XL-2000 Sonicator for 10×10 s at power setting 3 
(output wattage 6) followed by centrifugation at 8000 g for 1 min. 
A fraction (6%) of the supernatant was used as ‘input’. Clarified 
lysates were then incubated at 4 °C overnight with 2 μg of anti-
FLAG antibody (F7425, Sigma) and an equal volume of RIPA buf-
fer (50 mM Tris.HCl pH 8, 150 mM NaCl, 2 mM EDTA pH 8, 1% 
NP-40, 0.5% sodium deoxycholate, 0.1% SDS, and protease in-
hibitor). To each sample, 10 µL of Dynabeads Protein G (10003D, 
Novex) were added and incubated on a rotator at 4 °C for 2 h. 
Beads were washed 3 times with wash buffer (20 mM Tris–HCl 
pH 8.0, 150 mM NaCl, 2 mM EDTA pH 8, 1% Triton X-100, and 
0.1% SDS), and once with final wash buffer (20 mM Tris–HCl pH 
8.0, 500 mM NaCl, 2 mM EDTA pH 8, 1% Triton X-100, and 0.1% 
SDS). Bound complexes were eluted from the beads with elution 
buffer (100 mM NaHCO3 and 1% SDS) by incubating at 30 °C for 
20 min. Crosslinking was reversed by overnight incubation at 60–
65 °C in the presence of 10 µg/ml RNase A and 1 mg/ml Protein-
ase K. DNA was purified using Zymoclean Gel DNA Recovery Kit 
(D4002, Zymo Research). Immunoprecipitated and input material 
was analyzed by quantitative PCR (StepOne Plus Real Time PCR, 
Applied Biosystems) using SYBR green PCR mix (Applied Biosys-
tems) with three different primers sets as followed: G8Pro ChIP 
Fwd (5′-CTTCGTGGATCCTGTAGAACG-3′) and G8Pro ChIP Rev 
(5′-CCATCTTCCAGCGGATAGAATG-3′) which flank the G8 pro-
moter of pG8-Luc DNA; Neo Fwd (5′–CTTGCTCCTGCCGAGA-
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AAGT-3′) and Neo Rev (5′–TTCGCTTGGTGGTCGAATG-3′); and 
ActinB Fwd (5′–GGTCATCACTATTGGCAACG-3′) and ActinB Rev 
(5′–CGTCACACTTCATGATGGAATTG-3′). Serial dilutions were 
also included in each qPCR run and used to develop a standard 
curve and determine the PCR efficiency of the primer sets in that 
experiment set. The efficiency (E) is calculated as such: E=10(−1/
slope). Fold enrichment was calculated relative to negative control 
sets as such: fold enrichment=E−(ΔCttarget – ΔCtcontrol).
Statistics
Error bars shown represent one standard deviation from the 
mean. The p-values indicated were calculated using the Students 
t-test.
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Appendix A. Supplementary materials 
Figure S1. The defect in intermediate transcription specific to ts2 varies by cell type and does not correlate with variations in 
total BAF expression. (A). Transcription assays. Cells from each of the indicated lines were plated at equal numbers and transfected with pG8-
Luciferase for 7 h, then infected at 37 °C with WT or ts2 (MOI=3) in the presence of 50 μm Arac. Lysates were prepared at 16 h after infection and 
assayed for luciferase activity. RLU shown is normalized to total protein measured by BCA assay. Data were obtained from three independent ex-
periments performed in triplicate wells. Data from a representative experiment is shown. Error bars represent standard deviation. (* indicates a p-
value < 0.1, *** indicates a p-value < 0.05) (B). Immunoblot analysis of BAF expression. Lysates from equivalent numbers of cells were collected 
and analyzed using an antibody against BAF. The experiment was repeated twice and similar results obtained in each case.
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Figure S2. BAF immunoprecipitates Cellular and plasmid DNA in L929 cells. Raw Ct values from quantitative PCR study shown in Fig-
ure 4 using primers flanking the G8 promoter (A) or Neomycin resistance gene (B) of pG8-Luc DNA or the beta-actin cellular gene(C). Data shown 
is a representative from three independent experiments, each performed in duplicate. Error bars represent standard deviation.
